Some Environmental Toxicants Linked to Depressive Symptoms
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, July 9, 2024 -- Certain categories of environmental toxicants are associated with depressive symptoms, according to a study published online July 3 in JAMA Network Open.
Jianhui Guo, M.D., from the Institute of Child and Adolescent Health at Peking University in Beijing, and colleagues screened and assessed the associations between potential environmental toxicants and depressive symptoms among 3,427 participants from the 2013 to 2014 and 2015 to 2016 waves of the National Health and Nutrition Examination Survey. Exposures were assessed for 62 toxicants in 10 categories; the association with depression scores, measured by the 9-item Patient Health Questionnaire (PHQ-9), was examined.
The researchers identified associations between 27 chemical compounds or metals in six of 10 categories of environmental toxicants and the prevalence of depressive symptoms, including the volatile organic compound metabolites N-acetyl-S-(2 hydroxy-3-butenyl)-L-cysteine and total nicotine equivalent-2 (odds ratios, 1.74 and 1.42, respectively). Compared with women and older individuals, men and younger individuals seemed more vulnerable to environmental toxicants. Overall, 5 to 19 percent of the associations were mediated by peripheral white blood cell count.
"This research highlights the significance of preventing and regulating important environmental toxicants to gain fresh insights into preventing and potentially treating depression," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-10 07:15
Read more
- Nearly 160 Million Americans Harmed by Another's Drinking, Drug Use
- U.S. Diabetes Rates Rise to Nearly 1 in 6 Adults
- Child-Teacher Bond in Early Education Could Have Lasting Impact
- Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
- Costs for MS, Parkinson's and Alzheimer's Meds Keep Rising
- Low Zinc Levels Seen With Liver Cirrhosis, Hepatic Encephalopathy
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions